Day: July 10, 2023

NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) — MidCap Financial Investment Corporation (NASDAQ: MFIC) (the “Company”) announced today that it has rescheduled its earnings conference call to Wednesday August 2, 2023, at 5 p.m. Eastern Time. As previously announced, the Company will report results for the quarter ended June 30, 2023, after market close on Wednesday, August 2, 2023. The Company will host a conference call on Wednesday, August 2, 2023, at 5:00 p.m. Eastern Time. All interested parties are welcome to participate in the conference call by dialing (800) 343-4849 approximately 5-10 minutes prior to the call; international callers should dial (203) 518-9783. Participants should reference either MidCap Financial Investment Corporation Earnings or Conference ID: MFIC0802 when prompted. A simultaneous webcast of the conference...

Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve as a Novel Neuroendocrine Weight-Loss Therapeutic for this Patient Population CHATHAM, N.J., July 10, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 ‘POWER’ study of TNX-1900 (intranasal potentiated oxytocin) for the treatment of pediatric obesity at the Massachusetts General Hospital (MGH). The aim of the study is to investigate the efficacy and safety of TNX-1900 as a novel therapeutic agent to induce weight loss and improve indicators of cardiometabolic risk in adolescent patients with obesity. Tonix...

TORONTO, July 10, 2023 (GLOBE NEWSWIRE) — Halcones Precious Metals Corp. (TSX – V: HPM) (the “Company” or “Halcones”) announces that its wholly-owned subsidiary, Minera Los Halcones SpA, has made the scheduled option agreement payment pursuant to the option agreement (the “Option Agreement”) to maintain its option to acquire the Carachapampa project (the “Project”). As previously announced, Halcones and the optionor agreed to extend the deadline to make the next payment of USD$200,000 from April 7, 2023 to July 7, 2023 (Please see Halcones’ news release dated April 4, 2023). The extension enabled additional time for the Halcones technical team to fully evaluate the results of the recent 7 hole (1,526 m) drill campaign. With the additional analysis now complete, Halcones has paid the scheduled amount in full. Drill campaign highlights: Hole...

– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Plan – WATERTOWN, Mass., July 10, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Executive Officer (CEO). Dr. Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President. Dr. Duker has also been appointed to the Board of Directors of the Company, effective today. Nancy S. Lurker has transitioned to the role of Executive Vice Chair of the Board of Directors...

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors. TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration. The TNG462 phase 1/2 clinical trial will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in solid tumors with MTAP deletions. “Dosing the first patient with our next-generation MTA-cooperative PRMT5 inhibitor, TNG462, demonstrates our deep commitment to developing transformative treatments for patients with MTAP-deleted cancers....

TORONTO, July 10, 2023 (GLOBE NEWSWIRE) — Canadian North Resources Inc. (“the Company,” TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero)) is pleased to announce that Director and Chairman of the Company, Mr. Lee Shim purchased 100,000 shares of the Company’s common stock in the open market at a price of $2.20 per share. Complete details are available at SEDI.ca. This investment further reinforces Mr. Shim’s confidence in the Company’s growth potential and commitment to its long-term success. About Canadian North Resources Canadian North Resources Inc. is an exploration and development company focusing on the critical metals for the clean-energy, electric vehicles, battery and high-tech industries. The company is advancing its 100% owned Ferguson Lake nickel, copper, cobalt, palladium, and platinum project that...

Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration.Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density and increase in immune cell density, confirming the mechanism of action of both direct cytotoxic and immune-activating effects.Among all patients, median overall survival (OS) was 19.5 months. The median OS among patients who had malignant pleural mesothelioma (MPM) was 22 months.There were no dose-limiting toxicities or dose de-escalations, and the maximally tolerated dose was not reached. Therefore, a recommended dose was not established.WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ:...

Backlog of contracted projects increases to $6.1 million as demand for commercial solar intensifies TORONTO and KNOXVILLE, Tenn., July 10, 2023 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR), a leading solar energy solutions provider focused on the commercial and industrial solar sector, is pleased to announce it has signed contracts for the design, engineering, and construction of two commercial solar projects for a client in Tennessee. The first project is a ground mount system with a capacity of 250-kilowatts (“kW”) and a capital cost of $720,000. The second project is a ground mount system with a capacity of 299-kW and a capital cost of $860,000. The two projects, which are being constructed at separate facilities, are scheduled to begin construction in Q3 2023 and are currently...

Denver, CO, July 10, 2023 (GLOBE NEWSWIRE) — Intrepid Potash, Inc. (“Intrepid,” “we,” or “our”) (NYSE:IPI) today announced the successful completion of the Well 45 and Well 46 drilling projects at its solar solution potash mine in Moab, Utah. This is the second update on Intrepid’s major capital projects included in its 2023 capital program. Key Highlights & Management Commentary We successfully completed the Well 45 and Well 46 drilling projects at our solar solution potash mine in Moab, Utah, in time for the 2023 evaporation season. Both projects will help us deliver on our key goals of maximizing brine availability and underground brine residence time, which is expected to lead to improved brine grade and higher and more consistent production. Bob Jornayvaz, Intrepid’s Executive...